AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
(4) - EconoTimes)
MALVERN, Pa., Jan. 04, 2018 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology, today announced that, on January 2, 2018, the Compensation Committee of Aclaris’ Board of Directors granted 6 non-qualified stock option awards to purchase an aggregate of 35,800 shares of its common stock and 6 restricted stock unit awards covering an aggregate of 6,050 shares of its common stock to 6 new employees under the Aclaris 2017 Inducement Plan. The stock options and restricted stock units were granted as inducements material to the new employees becoming employees of Aclaris in accordance with NASDAQ Listing Rule 5635(c)(4).
The 2017 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Aclaris (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Aclaris, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
The options have an exercise price of $25.03 per share, which is equal to the closing price of Aclaris' common stock on January 2, 2018. Each option and restricted stock unit award will vest, and become exercisable (as applicable), as to twenty-five percent of the shares on each of the first, second, third and fourth anniversaries of the recipient's start date, subject to each such employee's continued employment with Aclaris on such vesting dates. The options and restricted stock unit awards are subject to the terms and conditions of Aclaris' 2017 Inducement Equity Plan, and the terms and conditions of a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. Aclaris is focused on large, underserved market segments with no FDA-approved medications or where treatment gaps exist. Aclaris is based in Malvern, Pennsylvania and more information can be found by visiting the Aclaris website at www.aclaristx.com.
Aclaris Contact
Michael Tung, M.D.
Investor Relations
484-329-2140
[email protected]
Media Contact
Mariann Caprino
TogoRun
917-242-1087
[email protected]
